Abstract: The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility.

Abstract: The present disclosure relates to a multilayer reinforced composite electrolyte membrane and a method for manufacturing the same. The multilayer reinforced composite electrolyte membrane according to the present disclosure has sufficient mechanical properties and improved membrane resistance at the same time since a porous support is impregnated in an ionomer and it is stacked in a multilayer structure. Furthermore, since the composite electrolyte membrane has no wrinkles and cracks due to excellent dimensional stability, it can improve the electrochemical properties of batteries.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver, containing dental tissue-derived mesenchymal stem cells cryopreserved by vitrification. The pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver, of the present invention, reduces body weight, lowers serum adipokine concentration, allows the liver to recover in view of histological findings, and improves lipid metabolic enzymes in the liver, thereby exhibiting remarkable prevention and treatment effects on obesity or non-alcoholic fatty liver. In addition, dental tissue-derived mesenchymal stem cells, which are the active ingredients of the present invention, are mesodermal stem cells having verified safety and may be obtained with the least invasiveness, and thus are expected to be effectively used as a cell therapeutic agent for obesity or non-alcoholic fatty liver.

Abstract: The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility.

Abstract: A mandrel of a coil box comprises: a cylindrical mandrel body having a center shaft disposed therein and a slot into which a front end portion of a hot bar is inserted; and a guide part which is arranged towards the inside of the mandrel body from a peripheral wall of one side of the slot so as to prevent the cooling and plastic deformation of the front end portion of the bar inserted through the slot.

Abstract: Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.

Abstract: Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described. Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.

Abstract: Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described. Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.

Abstract: Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.